(VEEV) Veeva Systems - Overview
Stock: Cloud, CRM, Vault, Clinical, Data
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 33.2% |
| Relative Tail Risk | -14.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.36 |
| Alpha | -24.28 |
| Character TTM | |
|---|---|
| Beta | 0.651 |
| Beta Downside | 0.629 |
| Drawdowns 3y | |
|---|---|
| Max DD | 33.41% |
| CAGR/Max DD | 0.14 |
Description: VEEV Veeva Systems January 29, 2026
Veeva Systems Inc. (NYSE: VEEV) delivers a suite of cloud-based software solutions tailored to the life-sciences sector, spanning commercial, data, development, and quality clouds. Its offerings include Veeva Vault CRM, Medical, PromoMats, and Crossix for brand-level analytics; Veeva OpenData, Link, Compass, and CRM Pulse for enriched customer and patient insights; and Veeva Clinical, Safety, RIM, and Quality platforms that streamline trial execution, regulatory compliance, and product quality. The company also provides professional services-implementation, consulting, training, and managed support-to help pharma, biotech, and consumer-product firms adopt and operate these solutions at scale.
Key recent metrics underscore Veeva’s growth trajectory: FY 2025 total revenue reached **$2.34 billion**, a **13.2 %** year-over-year increase driven primarily by a **22 %** rise in subscription ARR; gross margin held steady at **78 %**, reflecting the high-margin SaaS model. The life-sciences cloud market is expanding at an estimated **11 % CAGR** through 2028, propelled by rising R&D spend (global biotech R&D outlays grew **9 %** YoY) and regulatory pressure for digital compliance-both tailwinds that reinforce Veeva’s addressable market. Additionally, Veeva’s **OpenData** platform now covers **> 200 million** unique contacts, enhancing cross-sell opportunities across its product stack.
For a deeper quantitative view of VEEV’s valuation metrics, you may want to explore the ValueRay platform.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: 860.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.17 > 0.02 and ΔFCF/TA 0.39 > 1.0 |
| NWC/Revenue: 200.2% < 20% (prev 172.8%; Δ 27.41% < -1%) |
| CFO/TA 0.17 > 3% & CFO 1.38b > Net Income 860.3m |
| Net Debt (-1.57b) to EBITDA (908.7m): -1.73 < 3 |
| Current Ratio: 7.53 > 1.5 & < 3 |
| Outstanding Shares: last quarter (168.0m) vs 12m ago 1.80% < -2% |
| Gross Margin: 75.67% > 18% (prev 0.74%; Δ 7493 % > 0.5%) |
| Asset Turnover: 42.34% > 50% (prev 41.17%; Δ 1.17% > 0%) |
| Interest Coverage Ratio: -3.26 > 6 (EBITDA TTM 908.7m / Interest Expense TTM -263.2m) |
Altman Z'' 10.00
| A: 0.76 (Total Current Assets 7.11b - Total Current Liabilities 944.9m) / Total Assets 8.10b |
| B: 0.51 (Retained Earnings 4.12b / Total Assets 8.10b) |
| C: 0.12 (EBIT TTM 858.9m / Avg Total Assets 7.28b) |
| D: 3.91 (Book Value of Equity 4.13b / Total Liabilities 1.06b) |
| Altman-Z'' Score: 11.55 = AAA |
Beneish M -3.09
| DSRI: 1.06 (Receivables 371.8m/301.3m, Revenue 3.08b/2.66b) |
| GMI: 0.98 (GM 75.67% / 73.93%) |
| AQI: 0.76 (AQ_t 0.10 / AQ_t-1 0.14) |
| SGI: 1.16 (Revenue 3.08b / 2.66b) |
| TATA: -0.06 (NI 860.3m - CFO 1.38b) / TA 8.10b) |
| Beneish M-Score: -3.09 (Cap -4..+1) = AA |
What is the price of VEEV shares?
Over the past week, the price has changed by -9.04%, over one month by -7.09%, over three months by -30.34% and over the past year by -12.59%.
Is VEEV a buy, sell or hold?
- StrongBuy: 12
- Buy: 7
- Hold: 11
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the VEEV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 309.6 | 51.8% |
| Analysts Target Price | 309.6 | 51.8% |
| ValueRay Target Price | 202.7 | -0.6% |
VEEV Fundamental Data Overview January 28, 2026
P/E Forward = 25.7069
P/S = 11.9637
P/B = 5.1832
P/EG = 1.0037
Revenue TTM = 3.08b USD
EBIT TTM = 858.9m USD
EBITDA TTM = 908.7m USD
Long Term Debt = 89.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 10.5m USD (from shortTermDebt, last quarter)
Debt = 89.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.57b USD (from netDebt column, last quarter)
Enterprise Value = 30.30b USD (36.85b + Debt 89.8m - CCE 6.64b)
Interest Coverage Ratio = -3.26 (Ebit TTM 858.9m / Interest Expense TTM -263.2m)
EV/FCF = 22.37x (Enterprise Value 30.30b / FCF TTM 1.35b)
FCF Yield = 4.47% (FCF TTM 1.35b / Enterprise Value 30.30b)
FCF Margin = 43.98% (FCF TTM 1.35b / Revenue TTM 3.08b)
Net Margin = 27.93% (Net Income TTM 860.3m / Revenue TTM 3.08b)
Gross Margin = 75.67% ((Revenue TTM 3.08b - Cost of Revenue TTM 749.5m) / Revenue TTM)
Gross Margin QoQ = 75.41% (prev 75.26%)
Tobins Q-Ratio = 3.74 (Enterprise Value 30.30b / Total Assets 8.10b)
Interest Expense / Debt = 33.69% (Interest Expense 30.2m / Debt 89.8m)
Taxrate = 24.48% (76.6m / 312.8m)
NOPAT = 648.6m (EBIT 858.9m * (1 - 24.48%))
Current Ratio = 7.53 (Total Current Assets 7.11b / Total Current Liabilities 944.9m)
Debt / Equity = 0.01 (Debt 89.8m / totalStockholderEquity, last quarter 7.04b)
Debt / EBITDA = -1.73 (Net Debt -1.57b / EBITDA 908.7m)
Debt / FCF = -1.16 (Net Debt -1.57b / FCF TTM 1.35b)
Total Stockholder Equity = 6.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.83% (Net Income 860.3m / Total Assets 8.10b)
RoE = 13.38% (Net Income TTM 860.3m / Total Stockholder Equity 6.43b)
RoCE = 13.17% (EBIT 858.9m / Capital Employed (Equity 6.43b + L.T.Debt 89.8m))
RoIC = 10.09% (NOPAT 648.6m / Invested Capital 6.43b)
WACC = 8.35% (E(36.85b)/V(36.94b) * Re(8.31%) + D(89.8m)/V(36.94b) * Rd(33.69%) * (1-Tc(0.24)))
Discount Rate = 8.31% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.27%
[DCF Debug] Terminal Value 79.34% ; FCFF base≈1.23b ; Y1≈1.44b ; Y5≈2.17b
Fair Price DCF = 220.0 (EV 34.59b - Net Debt -1.57b = Equity 36.16b / Shares 164.4m; r=8.35% [WACC]; 5y FCF grow 17.99% → 2.90% )
EPS Correlation: 90.19 | EPS CAGR: 24.39% | SUE: 1.54 | # QB: 13
Revenue Correlation: 98.71 | Revenue CAGR: 14.67% | SUE: 1.91 | # QB: 8
EPS next Quarter (2026-04-30): EPS=2.06 | Chg30d=+0.000 | Revisions Net=+6 | Analysts=20
EPS next Year (2027-01-31): EPS=8.59 | Chg30d=+0.017 | Revisions Net=+4 | Growth EPS=+8.2% | Growth Revenue=+12.1%